AGA Medical Adds Jack P. Helms to Board of Directors

"Jack brings extensive knowledge of financial and capital markets, as
well as experience in several industries, including health care,
consumer and manufacturing," said Tommy Thompson, chairman of the board
of AGA Medical. "His insights will be valuable as AGA Medical grows as a
public company, and we look forward to working with him."

Helms has more than 20 years of experience in corporate finance.
Currently, he serves as chairman of Lazard Middle Market LLC (formerly
Goldsmith Agio Helms), a premier middle-market investment bank. During
his career, he has initiated and completed a wide range of mergers,
acquisitions, sales, divestitures, financings and recapitalizations,
including complex cross-border sales and international joint ventures,
and multifaceted sales of small-cap public companies. Previously, Helms
was a partner in an international law firm practicing in the area of
mergers and acquisitions, limited partnerships, and tax and corporate
law, and worked in corporate finance with a Fortune 100 company. Helms
also served as an independent director of Applebee's International, Inc.
from 1993 to 2007, when the company was sold. He served as co-chair of
the special committee that managed the sale process.

Helms is a member of the Association for Corporate Growth national board
of directors and chair of the ACG InterGrowth 2011 conference. Investment
Dealers' Digest named him 2007 Middle-Market Banker of the Year.
Helms is a graduate of the University of Michigan Law School magna cum
laude and Order of the Coif, and a member of the Minnesota bar. He
received his bachelor's degree from Iowa State University, and is a
certified public accountant and a member of the Minnesota Society of
CPAs.

About AGA Medical

AGA Medical, based in Plymouth, Minnesota, is a leading innovator and
manufacturer of medical devices for the treatment of structural heart
defects and vascular diseases. AGA Medical's AMPLATZER occlusion
devices offer minimally invasive, transcatheter treatments that have
been clinically shown to be highly effective in defect closure. The
Company's devices and delivery systems use relatively small catheters
and can be retrieved and repositioned prior to release from the delivery
cable, enabling optimal placement without the need to repeat the
procedure or use multiple devices. AGA Medical is the only manufacturer
with occlusion devices approved to close seven different structural
heart defects, with leading market positions for each of its devices.
More than 1,500 articles supporting the benefits of AMPLATZER products
have been published in medical literature. AGA Medical markets AMPLATZER
products in 112 countries worldwide. In addition to its presence with
cardiologists, AGA Medical has also leveraged its core competencies in
nitinol braiding and transcatheter delivery systems to develop products
for the treatment of certain vascular diseases, which are sold primarily
to interventional radiologists and vascular surgeons.

Forward-Looking Statements

This news release and any attachments may include "forward-looking
statements," within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, or the Exchange Act, including, in particular,
earnings guidance and any statements about the Company's plans,
strategies and prospects. These statements are based on the
beliefs of our management as well as assumptions made by, and
information currently available to, the Company. These statements
reflect the Company's current views with respect to future events, are
not guarantees of future performance and involve risks and
uncertainties that could cause actual performance or results to differ
materially from those expressed in or suggested by the forward-looking
statements. These factors include, among other things: failure to
implement the Company's business strategy; failure to capitalize on the
Company's expected market opportunities; lack of regulatory approval and
market acceptance of the Company's new products, product enhancements or
new applications for existing products; regulatory developments in key
markets for the Company's AMPLATZER occlusion devices; failure to
complete the Company's clinical trials or failure to achieve the desired
results in our clinical trials; inability to successfully commercialize
the Company's existing and future research and development programs;
failure to protect the Company's intellectual property; intellectual
property claims exposure, related litigation expense, and any resultant
damages, awarded royalties or other remedies, in particular resulting
from our Medtronic and Occlutech litigations; competition; decreased
demand for the Company's products; product liability claims exposure;
failure to otherwise comply with laws and regulations; changes in
general economic and business conditions; changes in currency exchange
rates and interest rates; and other risks and uncertainties, including
those detailed in the Company's Registration Statement on Form
S-1 relating to its initial public offering, as well as from time to
time in the Company's periodic reports filed with the Securities and
Exchange Commission. You should not put undue reliance on any
forward-looking statements. You should understand that many important
factors, including those discussed herein, could cause the Company's
results to differ materially from those expressed or suggested in any
forward-looking statement. Except as required by law, the Company does
not undertake any obligation to update or revise these forward-looking
statements to reflect new information or events or circumstances that
occur after the date of this news release or to reflect the occurrence
of unanticipated events or otherwise. Readers are advised to review the
Company's filings with the Securities and Exchange Commission (which are
available from the SEC's EDGAR database at www.sec.gov,
at various SEC reference facilities in the United States and via the
Company's website at www.amplatzer.com).

For more information, visit www.amplatzer.com.

SOURCE: AGA Medical Holdings, Inc.

Padilla Speer Beardsley 
Nick Banovetz, 612-455-1705 
nbanovetz@psbpr.com

For full details on (AGAM) AGAM. (AGAM) has Short Term PowerRatings at TradingMarkets. Details on (AGAM) Short Term PowerRatings is available at This Link.